Literature DB >> 12555211

Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).

Joseph Schwartz1, Melissa D Leber, Shmuel Gillis, Austin Giunta, Amiram Eldor, James B Bussel.   

Abstract

Splenectomy is the only treatment of ITP known to have "curative" effects in a substantial fraction of patients. However, the true long-term outcome is uncertain and controversial because published series have not adjusted for the duration of follow-up. This IRB-approved retrospective study included all patients with ITP who underwent splenectomy between 1988-1993 at three major medical centers and required a minimum postoperative 5-year follow-up. Complete response (CR) was defined as all postsplenectomy platelet counts >150 x 10(9)/L without treatment; partial response (PR) as platelet counts > or =50 x 10(9)/L without treatment; and failure as platelet counts <50 x 10(9)/L or receiving therapy after splenectomy. Seventy-five patients identified with ITP underwent splenectomy from 1988 to 1993. Three patients died prior to 5-year follow-up, and 56 of the 72 patients (78%) were evaluable with follow-up for five years or longer, median 7.5 years. The immediate postoperative complete remission rate was 77%; 57% of patients have remained in prolonged CR. Thirty-seven patients (66%) have not required any therapy after splenectomy. Eight patients had platelet counts >150 x 10(9)/L for 4-8.5 years before relapsing; no clear plateau was attained in the remission curve. There was no operative mortality. Ten patients (18%) reported minor postoperative bleeding episodes. No life-threatening infections, significant heart disease, or pulmonary hypertension developed after splenectomy in the 434 patient-years of follow-up. This study helps to define the long-term results of splenectomy for ITP. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12555211     DOI: 10.1002/ajh.10253

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  28 in total

Review 1.  Immune thrombocytopenia: no longer 'idiopathic'.

Authors:  Keith McCrae
Journal:  Cleve Clin J Med       Date:  2011-06       Impact factor: 2.321

2.  The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.

Authors:  Ishac Nazi; John G Kelton; Mark Larché; Denis P Snider; Nancy M Heddle; Mark A Crowther; Richard J Cook; Alan T Tinmouth; Joy Mangel; Donald M Arnold
Journal:  Blood       Date:  2013-07-12       Impact factor: 22.113

3.  Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.

Authors:  Rachael F Grace; Jenny M Despotovic; Carolyn M Bennett; James B Bussel; Michelle Neier; Cindy Neunert; Shelley E Crary; Yves D Pastore; Robert J Klaassen; Jennifer A Rothman; Kerry Hege; Vicky R Breakey; Melissa J Rose; Kristin A Shimano; George R Buchanan; Amy Geddis; Kristina M Haley; Adonis Lorenzana; Alexis Thompson; Michael Jeng; Ellis J Neufeld; Travis Brown; Peter W Forbes; Michele P Lambert
Journal:  Am J Hematol       Date:  2018-05-06       Impact factor: 10.047

4.  CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Authors:  Li Ma; Elisa Simpson; June Li; Min Xuan; Miao Xu; Laura Baker; Yan Shi; Issaka Yougbaré; Xiaozhong Wang; Guangheng Zhu; Pingguo Chen; Gerald J Prud'homme; Alan H Lazarus; John Freedman; Heyu Ni
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

Review 5.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

6.  Autoimmune manifestations in aged mice arise from early-life immune dysregulation.

Authors:  Tamer I Mahmoud; Jingya Wang; Jodi L Karnell; Qiming Wang; Shu Wang; Brian Naiman; Phillip Gross; Philip Z Brohawn; Chris Morehouse; Jordan Aoyama; Clive Wasserfall; Laura Carter; Mark A Atkinson; David V Serreze; Helen Braley-Mullen; Tomas Mustelin; Roland Kolbeck; Ronald Herbst; Rachel Ettinger
Journal:  Sci Transl Med       Date:  2016-10-19       Impact factor: 17.956

7.  Prognostic factors of response to laparoscopic splenectomy in patients with idiopathic thrombocytopenic purpura.

Authors:  Hyuk-Chan Kwon; Chang-Hoon Moon; Young-Rak Cho; Min-Chan Kim; Kyeong-Hee Kim; Jin-Yeong Han; Young-Ho Lee; Sung-Yong Oh; Sung-Hyun Kim; Jae-Seok Kim; Hyo-Jin Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

8.  Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle.

Authors:  Andreas Rank; Oliver Weigert; Helmut Ostermann
Journal:  Biologics       Date:  2010-05-25

9.  Long-term outcomes of a 5-year follow up of patients with immune thrombocytopenic purpura after splenectomy.

Authors:  Jae Joon Han; Sun Kyung Baek; Jae Jin Lee; Si-Young Kim; Kyung Sam Cho; Hwi-Joong Yoon
Journal:  Korean J Hematol       Date:  2010-09-30

10.  T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy.

Authors:  P F Fogarty; M E Rick; W Zeng; A M Risitano; C E Dunbar; J B Bussel
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.